1. 诱导疾病模型产品 Vitamin D Related/Nuclear Receptor
  2. 遗传工程疾病模型 Estrogen Receptor/ERR
  3. 4-Hydroxytamoxifen

4-Hydroxytamoxifen  (Synonyms: 4-羟基他莫昔芬; (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene)

目录号: HY-16950 纯度: 99.95%
COA 产品使用指南

4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) 是一种口服有效,选择性的雌激素受体调节剂 (SERM)。4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) 基于 ER 介导的细胞核易位诱导 CRISPR/Cas9 系统。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

4-Hydroxytamoxifen Chemical Structure

4-Hydroxytamoxifen Chemical Structure

CAS No. : 68047-06-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥639
In-stock
5 mg ¥750
In-stock
10 mg ¥950
In-stock
25 mg ¥2050
In-stock
50 mg ¥4000
In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Other Forms of 4-Hydroxytamoxifen:

查看 Estrogen Receptor/ERR 亚型特异性产品:

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) induces CRISPR/Cas9 systems based on ER mediated nucleus translocation[1][2][3][4].

IC50 & Target[1][2]

Estrogen receptor

3.3 nM (IC50)

CRISPR/Cas9

 

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
DU-145 EC50
10 μM
Compound: OH-TAM
Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay
Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay
[PMID: 25198997]
DU-145 IC50
15.3 μM
Compound: 4OHT
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 33965842]
HEK293 IC50
0.07 μM
Compound: 4-OHT
Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay
Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay
[PMID: 26613635]
HEK293 IC50
0.79 nM
Compound: 4-OHT
Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay
Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay
[PMID: 30940565]
Ishikawa EC50
11.5 μM
Compound: OH-TAM
Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay
Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay
[PMID: 25198997]
Ishikawa IC50
3.57 μg/mL
Compound: 4-Hydroxy-Tamoxifen
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MCF-10A IC50
10 μM
Compound: OH-TAM
Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
[PMID: 25198997]
MCF-10A IC50
21.5 μM
Compound: 4OHT
Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
[PMID: 35611405]
MCF7 IC50
0.0034 μM
Compound: 4-hydroxytamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
[PMID: 28105283]
MCF7 IC50
0.15 μM
Compound: 4-OHT
Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay
Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay
[PMID: 26613635]
MCF7 IC50
0.67 μM
Compound: 4OHT
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
[PMID: 35611405]
MCF7 IC50
0.95 μg/mL
Compound: 4-Hydroxy-Tamoxifen
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MCF7 IC50
10.1 μM
Compound: 4-OHT
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
[PMID: 30939353]
MCF7 IC50
15.6 μM
Compound: 4OHT
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 33965842]
MCF7 IC50
17.5 μM
Compound: 4-hydroxytamoxifen
Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
[PMID: 31465222]
MCF7 IC50
20 μM
Compound: 4-hydroxytamoxifen
Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
[PMID: 28105283]
MCF7 EC50
3.5 nM
Compound: 2a; 4OH-T
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
[PMID: 34251202]
MCF7 EC50
7.4 μM
Compound: OH-TAM
Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay
[PMID: 25198997]
MCF7 EC50
8.8 μM
Compound: OH-TAM
Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay
[PMID: 25198997]
MCF7 IC50
9.5 μM
Compound: 4OHT
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 30053783]
MCF7 IC50
9.9 nM
Compound: 2
Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay
Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay
[PMID: 29562737]
MDA-MB-231 IC50
18.43 μM
Compound: 4OHT
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
[PMID: 35611405]
MDA-MB-231 IC50
6.51 μg/mL
Compound: 4-Hydroxy-Tamoxifen
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MDA-MB-231 EC50
7.8 μM
Compound: OH-TAM
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay
[PMID: 25198997]
MDA-MB-231 EC50
8 μM
Compound: OH-TAM
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 25198997]
T47D IC50
0.01 μM
Compound: 4-OHT
Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay
Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay
[PMID: 26613635]
Vero IC50
15.1 μM
Compound: 4OHT
Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 33965842]
体外研究
(In Vitro)

4-Hydroxytamoxifen (Monohydroxytamoxifen) 是一种选择性雌激素受体拮抗剂,[3H]oestradiol 与雌激素受体结合的 IC50 为 3.3 nM。4-Hydroxytamoxifen (10,100 nM) 能够抑制[3H]oestradiol 与人 8 S 雌激素受体的结合[1]
4-Hydroxytamoxifen 激活内含肽连接的无活性 Cas9,减少脱靶 CRISPR 介导的基因编辑。在人类细胞中,有条件激活的 Cas9 修饰靶基因组位点的特异性比野生型 Cas9 高 25 倍[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

4-Hydroxytamoxifen (0.2、1 和 5 μg/d,口服) 引起未成熟大鼠子宫湿重剂量相关降低[1]
4-Hydroxytamoxifen (6 μg/0.1 mL 芝麻油,每天 1 次,皮下注射) 有效减弱完整和切除性腺的 C57BL/6 J 小鼠的两性中甲基苯丙胺诱导的黑质纹状体多巴胺耗竭。4-Hydroxytamoxifen 不会改变纹状体中的多巴胺含量水平[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

387.52

Formula

C26H29NO2

CAS 号
性状

固体

颜色

White to off-white

中文名称

4-羟基他莫昔芬

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 50 mg/mL (129.03 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 20 mg/mL (51.61 mM; 超声助溶)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5805 mL 12.9026 mL 25.8051 mL
5 mM 0.5161 mL 2.5805 mL 5.1610 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (5.37 mM); 澄清溶液

    此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (5.37 mM); 澄清溶液

    此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

  • 方案 一

    请依序添加每种溶剂: 50% PEG300    50% Saline

    Solubility: 5 mg/mL (12.90 mM); 悬浊液; 超声助溶

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.96%

参考文献
Kinase Assay
[1]

Cytosol (200 μL) is incubated for 30 min at 4°C with different concentrations of oestradiol, tamoxifen and (4-Hydroxytamoxifen) or dihydroxytamoxifen administered in 10 μL methanol. Control tubes are incubated with 10 μL methanol alone and non-specific binding is determined in a parallel incubation of cytosol (200 μL) with methanol (10 μL) containing DES (5 × 106 M). [2,4,6,7-3H]Oestradiol solution (50 μL) in TED buffer is added to each tube to give a final concentration of 2 × 10-9 M. Incubation is continued for 4 h (4°C) and then 400 μL of a suspension of dextran-coated charcoal (250 mg % Norit A, 2.5 mg % dextran) in TED buffer are added and allowed to stand for 20 min. Tubes are centrifuged at 800 g for 10 min (4°C) and 400 μL samples of the supernatant are added to 10 mL tritium scintillator (6 g butyl PBD, 135 mL toluene, 720 ml dioxan, 100 g naphthalene, 45 mL absolute methanol). Samples are counted for 10 min in a liquid scintillation spectrometer. Counting efficiency is determined by external standardization (35-36 %). Results are represented as a percentage of the specifically bound radioactivity (c.p.m.) in the control tubes[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Mice[3]
Animals of each sex are divided into two groups: one group receives 4-Hydroxytamoxifen [6 μg/0.1 mL sesame oil/day, subcutaneously (s.c.) starting at 06.00 h] injections for three consecutive days, while the other group receives an equivalent amount of sesame oil injection for 3 days. Four hours following the third injection, each group is then subdivided into two groups: one receives four cumulative doses of methamphetamine hydrochloride (10 mg/kg, s.c.), and the other receives a comparable volume of saline at 2-h intervals. Bilateral gonadectomy is performed under pentobarbital anesthesia (50 mg/kg, intraperitoneally). Five weeks after surgery,gonadectomized mice of each sex are randomly divided into six groups. Five groups of each sex receive three daily injections ofvarious concentrations of 4-Hydroxytamoxifen (0, 1.5, 3.0, 6.0, and 12.0 μg/0.1 mL sesame oil/day). Four hours following the third injection, mice receive four doses of methamphetamine (MA, 10 mg/kg) at 2-h intervals. The remaining group of each sex receives sesame oil pretreatment for three consecutive days, followed by saline injections, and serves as the control group[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.5805 mL 12.9026 mL 25.8051 mL 64.5128 mL
5 mM 0.5161 mL 2.5805 mL 5.1610 mL 12.9026 mL
10 mM 0.2581 mL 1.2903 mL 2.5805 mL 6.4513 mL
15 mM 0.1720 mL 0.8602 mL 1.7203 mL 4.3009 mL
20 mM 0.1290 mL 0.6451 mL 1.2903 mL 3.2256 mL
25 mM 0.1032 mL 0.5161 mL 1.0322 mL 2.5805 mL
30 mM 0.0860 mL 0.4301 mL 0.8602 mL 2.1504 mL
40 mM 0.0645 mL 0.3226 mL 0.6451 mL 1.6128 mL
50 mM 0.0516 mL 0.2581 mL 0.5161 mL 1.2903 mL
DMSO 60 mM 0.0430 mL 0.2150 mL 0.4301 mL 1.0752 mL
80 mM 0.0323 mL 0.1613 mL 0.3226 mL 0.8064 mL
100 mM 0.0258 mL 0.1290 mL 0.2581 mL 0.6451 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
4-Hydroxytamoxifen
目录号:
HY-16950
需求量: